IP Library Granted Patent US 10,251,918
Granted Patent B2
US 10,251,918 · App. 14/891,533 · Granted Apr 9, 2019

Preventive or therapeutic agent for ruminant animal mastitis

Inventors: Nobuhisa Ashida (Kanagawa, JP); Tomokazu Imabayashi (Kanagawa, JP); Hisashi Aso (Miyagi, JP)
Assignee: Asahi Calpis Wellness Co., Ltd.
A61K35/742A23K1/009A23K1/1813A23K10/18A23K50/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,251,918
App. No.
14/891,533
Granted
Apr 9, 2019
Kind
B2
Abstract

The present invention relates to a substance or method for preventing or treating mastitis in ruminant animals, particularly in dairy cows. Specifically provided are: a preventive or therapeutic agent, a feed additive, a feed, and a pharmaceutical composition for ruminant animal mastitis, characterized by comprising, as an active ingredient, a Bacillus genus bacterium having the property of being capable of increasing or maintaining CD11c + CD172a + blood dendritic cell gate 2 in cows.

Claims (10)

1. A method for enhancing a preventive or therapeutic effect of a feed for female cows on cow mastitis, comprising:

adding a feed additive for the prevention or therapy of cow mastitis to the feed for female cows, wherein the feed additive comprises, as an active ingredient, Bacillus subtilis strain C-3102 (international accession number: FERM BP-1096); and

administering the feed to a female cow, for a period from 1 month before cow delivery to 3 months after the delivery, in an amount effective to prevent the development of cow mastitis in the female cow, or to treat cow mastitis if the female cow is affected with mastitis.

2. The method according to claim 1 , wherein the female cow is a dairy cow.

3. The method according to claim 1 , the feed additive further comprises an antibiotic for the therapy of mastitis.

4. The method according to claim 1 , wherein the Bacillus subtilis strain C-3102 (international accession number: FERM BP-1096) is orally administered to the female cow at a dose of 1×10 5 cells/day/animal or more.

5. A method for the prevention or therapy of mastitis in a female cow, comprising administering a preventive or therapeutic agent to the female cow in need thereof for a period from 1 month before cow delivery to 3 months after the delivery, wherein the preventive or therapeutic agent comprises, as an active ingredient, Bacillus subtilis strain C-3102 (international accession number: FERM BP-1096), and the preventative or therapeutic agent is administered in an amount effective to prevent the development of mastitis in the female cow, or to treat mastitis if the female cow is affected with mastitis.

6. The method according to claim 5 , further comprising administering an antibiotic for the therapy of mastitis, if necessary.

7. The method according to claim 5 , wherein the Bacillus subtilis strain C-3102 (international accession number: FERM BP-1096) is orally administered to the female cow at a dose of 1×10 5 cells/day/animal or more.

8. The method according to claim 5 , wherein the female cow is a dairy cow.

Assignments (3)
CHANGE OF NAME Recorded Sep 11, 2020
From: ASAHI CALPIS WELLNESS CO., LTD.
To: ASAHI BIOCYCLE CO., LTD.
Reel/Frame 053740/0891 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 15, 2016
From: ASHIDA, NOBUHISA; IMABAYASHI, TOMOKAZU; ASO, HISASHI
To: CALPIS CO., LTD.
Reel/Frame 037500/0965 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 15, 2016
From: CALPIS CO., LTD.
To: ASAHI CALPIS WELLNESS CO., LTD.
Reel/Frame 037501/0109 →
Priority Claims (1)
JP 2013-105425 · May 17, 2013 · national
Continuity (1)
Related Publication 20160120919A1 · May 5, 2016